Y-mAbs Therapeutics, Inc.

NASDAQ:YMAB

13.57 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q1
Revenue 22.79819.93123.36320.45420.75120.25131.44712.53710.79710.4869.5988.96510.9515.38320.75000000000000000
Cost of Revenue 3.0142.1472.0392.6454.6492.0832.022.4751.241.8311.4610.550.410.0932.203000000000000000
Gross Profit 19.78417.78421.32417.80916.10218.16829.42710.0629.5578.6558.1378.41510.5415.2918.547000000000000000
Gross Profit Ratio 0.8680.8920.9130.8710.7760.8970.9360.8030.8850.8250.8480.9390.9630.9830.894000000000000000
Reseach & Development Expenses 12.34113.26713.38815.35812.05513.41819.78722.45326.4222.91228.75723.13119.77821.57924.01121.00530.05918.62216.82719.6614.49412.51111.0418.7318.2936.2046.6253.0762.3032.303
General & Administrative Expenses 0000000000000014.6311.63610.3938.1256.9314.6994.143.7423.0372.6841.9651.2752.650.7660.7610.761
Selling & Marketing Expenses 000000000000000000000000000000
SG&A 17.23211.42511.13510.211.2712.25110.79313.62623.08213.43815.13813.98813.47511.9714.6311.63610.3938.1256.9314.6994.143.7423.0372.6841.9651.2752.650.7660.7610.761
Other Expenses 0000000.10000.210062.012.2030000000.3190-0.011000.0210.01500
Operating Expenses 29.57324.69224.52325.55823.32525.66930.5836.07949.50236.3543.89537.11933.25333.54938.64132.64140.45226.74723.75824.35918.63416.25314.07811.41510.2587.4799.2753.8423.0413.041
Operating Income -9.789-6.908-3.199-7.749-7.223-7.501-1.153-26.017-39.945-27.695-35.758-28.704-22.712-28.259-20.094-32.641-40.452-26.747-23.758-24.359-18.634-16.253-14.078-11.415-10.258-7.479-9.275-3.842-3.064-3.064
Operating Income Ratio -0.429-0.347-0.137-0.379-0.348-0.37-0.037-2.075-3.7-2.641-3.726-3.202-2.074-5.25-0.968000000000000000
Total Other Income Expenses Net 0.640.4392.4060.1891.11.1112.31-1.509-1.186-0.373-1.135-0.154-0.22562.010.161-0.1910.0590.5680.6220.4370.5980.3190.018-0.011-0.047-0.0040.0210.0150.0230.023
Income Before Tax -9.149-6.469-0.793-7.56-6.123-6.391.157-27.526-41.131-28.068-36.893-28.858-22.93733.413-19.933-32.832-40.393-26.179-23.136-23.922-18.036-15.934-14.06-11.426-10.305-7.483-9.254-3.827-3.041-3.041
Income Before Tax Ratio -0.401-0.325-0.034-0.37-0.295-0.3160.037-2.196-3.809-2.677-3.844-3.219-2.0956.207-0.961000000000000000
Income Tax Expense 0.10.160.1950.1870.179-1.2931.5581.5091.1860.3731.1350-0.2160.3382.086000-0.07900-0.019000-7.479-9.275-3.8420.0230.023
Net Income -9.249-6.629-0.988-7.747-6.302-5.097-0.401-29.035-42.317-28.441-36.893-28.858-22.93733.413-19.933-32.832-40.393-26.179-23.136-23.922-18.036-15.934-14.06-11.426-10.305-7.483-9.254-3.827-3.041-3.041
Net Income Ratio -0.406-0.333-0.042-0.379-0.304-0.252-0.013-2.316-3.919-2.712-3.844-3.219-2.0956.207-0.961000000000000000
EPS -0.21-0.15-0.023-0.18-0.14-0.12-0.009-0.66-0.97-0.65-0.85-0.66-0.530.8-0.48-0.82-1.01-0.66-0.61-0.7-0.53-0.47-0.41-0.42-0.32-0.22-0.28-0.11-0.17-0.17
EPS Diluted -0.21-0.15-0.023-0.18-0.14-0.12-0.009-0.66-0.97-0.65-0.85-0.66-0.530.75-0.45-0.82-1.01-0.66-0.58-0.7-0.53-0.47-0.41-0.42-0.32-0.22-0.28-0.11-0.17-0.17
EBITDA -9.636-6.749-3.038-7.749-7.223-7.501-1.153-25.791-39.757-27.5-35.758-28.559-22.712-28.129-17.891-32.548-40.352-26.661-23.758-24.311-18.614-16.253-14.064-11.406-10.252-7.479-9.275-3.8420.0230.023
EBITDA Ratio -0.423-0.339-0.13-0.379-0.348-0.37-0.037-2.057-3.682-2.623-3.726-3.186-2.074-5.226-0.862000000000000000